Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies (Q38528048)

3 September 2017

1 reference

title

Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies (English)

1 reference

3 September 2017

1 reference

Kian Fan Chung

1

1 reference

3 September 2017

language of work or name

English

0 references

publication date

15 June 2015

1 reference

Journal of Internal Medicine

3 September 2017

published in

1 reference

3 September 2017

volume

279

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

192-204

1 reference

Hay fever, hygiene, and household size

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Cluster analysis and clinical asthma phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Identification of asthma clusters in two independent Korean adult asthma cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Asthma phenotypes in Japanese adults - their associations with the CCL5 and ADRB2 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Cluster analysis of obesity and asthma phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Three phenotypes of adult-onset asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Innate lymphoid cells in inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

TH2, allergy and group 2 innate lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Increased IL-33 expression by epithelial cells in bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Effects of anticytokine therapy in a mouse model of chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

T helper 17 cells in airway diseases: from laboratory bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Epithelial cell proliferation contributes to airway remodeling in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Airway smooth muscle thickness in asthma is related to severity but not duration of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 8-isoprostanes in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Fibrocyte localization to the airway smooth muscle is a feature of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Increased phenotypic differentiation and reduced corticosteroid sensitivity of fibrocytes in severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Increased TGF-beta2 in severe asthma with eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Importance of concomitant local and systemic eosinophilia in uncontrolled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Full blood count parameters for the detection of asthma inflammatory phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Impaired macrophage phagocytosis of bacteria in severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Bacteria in sputum of stable severe asthma and increased airway wall thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Effects of montelukast and beclomethasone on airway function and asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

"Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Biomarker-based asthma phenotypes of corticosteroid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Defining phenotypes in asthma: a step towards personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Targeting interleukin-4 in asthma: lost in translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Mepolizumab treatment in patients with severe eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Effects of an anti-TSLP antibody on allergen-induced asthmatic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Disordered microbial communities in asthmatic airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

A trial of clarithromycin for the treatment of suboptimally controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

An integrative systems biology approach to understanding pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

Application of 'omics technologies to biomarker discovery in inflammatory lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12382

21 January 2018

Identifiers

DOI

10.1111/JOIM.12382

1 reference

3 September 2017

1 reference